News about Drug Discovery & Development

Lupin Gets Tentative Approval from FDA for Olopatadine Hydrochloride Ophthalmic Solution

Lupin has received a tentative approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7 percent (OTC).

Drug Discovery & Development | 28/06/2024 | By Aishwarya |  677

WACKER & CordenPharma Enter Pandemic Readiness State for Germany

WACKER and CordenPharma have officially entered the pandemic readiness state as of June 1, 2024.

Drug Discovery & Development | 25/06/2024 | By Aishwarya |  353

Ethypharm Signs Deal with MTPC to Acquire Argatroban Monohydrate

Ethypharm has signed an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) to acquire the selective antithrombin agent, Argatroban monohydrate (Argatra, Arganova, Novastan, Exembol), in Europe.

Drug Discovery & Development | 18/06/2024 | By Aishwarya |  880

Sun Pharma, Moebius Medical Anti-Osteoarthritis Injection Offers Sustained Pain Relief in Clinical Trials

Sun Pharmaceutical Industries and Moebius Medical have presented data demonstrating the durability of pain relief achieved in symptomatic knee OA patients through 26 weeks post injection of MM-II.

Drug Discovery & Development | 15/06/2024 | By Aishwarya |  584

Glenmark Gets ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Glenmark has secured final approval by the United States Food & Drug Administration (US FDA) for Esomeprazole Magnesium Delayed-Release Capsules.

Drug Discovery & Development | 15/06/2024 | By Aishwarya |  363

Akums Launches Rabeprazole + Levosulpiride SR Capsules

Akums Akums Drugs & Pharmaceuticals Ltd. announced that it has launched Rabeprazole + Levosulpiride SR Capsules. Approved by the Drug Controller General of India (DCGI), the company claims this new formulation aims to enhance relief for patients suffering from gastrointestinal tract (GIT) disorders.

Drug Discovery & Development | 14/06/2024 | By Manvi |  820

AbbVie and FutureGen to Develop Next-Gen Therapy for Inflammatory Bowel Disease

AbbVie has signed a license agreement with FutureGen Biopharmaceutical to develop FG-M701, a next-generation TL1A antibody for the treatment of IBD currently in preclinical development.

Drug Discovery & Development | 14/06/2024 | By Aishwarya |  469

Streck, Longhorn Vaccines and Diagnostics to Distribute PrimeStore MTM Globally

Streck has joined forces with Longhorn Vaccines and Diagnostics to distribute its flagship product, PrimeStore Molecular Transport Media (MTM), worldwide.

Drug Discovery & Development | 12/06/2024 | By Aishwarya |  270

ALZpath Signs Licensing Deal with Roche for Use of pTau217 Antibody in Blood Test

ALZpath, Inc. has signed a strategic license agreement with Roche for the use of the ALZpath pTau217 antibody to develop and commercialize an Alzheimer's disease diagnostic blood test.

Drug Discovery & Development | 11/06/2024 | By Aishwarya |  802

Amneal Expands Broad Injectables Portfolio with Addition of Six New Therapies

Amneal Pharmaceuticals has expanded its injectables portfolio with six new injectable product launches during the second quarter of 2024.

Drug Discovery & Development | 11/06/2024 | By Aishwarya |  582